Unlock stock picks and a broker-level newsfeed that powers Wall Street.

HKSE - Delayed Quote HKD

Antengene Corporation Limited (6996.HK)

Compare
2.670
+0.070
+(2.69%)
At close: April 17 at 4:08:07 PM GMT+8
Currency in CNY All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
67,305
67,305
160,135
28,769
--
Cost of Revenue
12,293
12,293
28,131
4,580
--
Gross Profit
55,012
55,012
132,004
24,189
--
Operating Expense
716,583
716,583
1,000,511
618,463
488,490
Operating Income
-661,571
-661,571
-868,507
-594,274
-488,490
Net Non Operating Interest Income Expense
37,885
37,885
27,230
17,134
11,170
Pretax Income
-581,183
-581,183
-601,488
-655,529
-2,928,921
Net Income Common Stockholders
-581,183
-581,183
-601,488
-655,529
-2,928,921
Diluted NI Available to Com Stockholders
-581,183
-581,183
-601,488
-655,529
-2,928,921
Basic EPS
-0.94
-0.94
-0.97
-1.05
-11.66
Diluted EPS
-0.94
-0.94
-0.97
-1.05
-11.66
Basic Average Shares
615,438.058
615,438.058
617,822.464
624,989.465
251,098.557
Diluted Average Shares
615,438.058
615,438.058
617,822.464
624,989.465
251,098.557
Rent Expense Supplemental
2,414
--
--
--
--
Total Expenses
728,876
728,876
1,028,642
623,043
488,490
Net Income from Continuing & Discontinued Operation
-581,183
-581,183
-601,488
-655,529
-2,928,921
Normalized Income
-581,705
-581,705
-601,488
-655,872
-2,928,965
Interest Income
38,783
38,783
28,204
17,832
12,202
Interest Expense
898
898
974
698
1,032
Net Interest Income
37,885
37,885
27,230
17,134
11,170
EBIT
-580,285
-580,285
-600,514
-654,831
-2,927,889
EBITDA
-550,311
-550,311
-573,314
-643,334
-2,923,800
Reconciled Cost of Revenue
12,293
12,293
28,131
4,580
--
Reconciled Depreciation
29,974
29,974
27,200
11,497
4,089
Net Income from Continuing Operation Net Minority Interest
-581,183
-581,183
-601,488
-655,529
-2,928,921
Total Unusual Items Excluding Goodwill
522
522
--
343
44
Total Unusual Items
522
522
--
343
44
Normalized EBITDA
-550,833
-550,833
-573,314
-643,677
-2,923,844
12/31/2020 - 11/20/2020

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

2142.HK HBM Holdings Limited
7.180
0.00%
 
6998.HK Genor Biopharma Holdings Limited
2.060
-1.90%
 
1952.HK Everest Medicines Limited
47.100
+1.07%
 
1672.HK ASCLETIS-B
4.940
-4.63%
 
OLMA Olema Pharmaceuticals, Inc.
4.4200
+3.76%
 
NAMS NewAmsterdam Pharma Company N.V.
16.34
+1.93%
 
MGNX MacroGenics, Inc.
1.2600
+6.78%
 
NLSP NLS Pharmaceutics AG
1.4600
+2.10%
 
KPTI Karyopharm Therapeutics Inc.
4.9500
+11.99%
 
RNAZ TransCode Therapeutics, Inc.
0.2725
-23.58%